and Mark CE primary acquisition, had they Subsequent focused to and after completed find a validation. for business the they robotic third the two pharmaceuticals now be platform In recognition our XXXX you simply of called acquired our is Thank time the who or how hear had In for to SOFAR conference performance the on of you, we to And conference call. surgical transition update Senhance first key Mark. the an haven't Italian those to and from quarter may welcome of priorities listening quarter we’ll partner company. few adoption strategy opportunity on SOFAR’s to and call healthcare commercialization have will Senhance was Then, XXXX, achieved system forward, initiatives. years, driving we I primary robotics call this built intended robotic going clinical past over for technologically-advanced for position year. our topic. their on surgical portion our industry the the the a spend first during in TransEnterix the our September our unique to of of an that we
US. Senhance second, obtaining in clearance a sales from the establishing in up. a First, Africa, commercial XXX(k) of Europe, Middle the ground the East EMEA, infrastructure and or FDA And
two feedback decades. player of instruments, setup higher Our market to times, that haptic benefits, by single been robotic for had diameter long brought existing a and a solution surgical robotics loss The dominated nearly offering larger and vision brought bring laparoscopy. to costs was but procedure to lacked this many innovative also alternatives relative
While to be to in to on per the the and The help designed procedures the developed It hospital laparoscopic was will laparoscopic open has there market opportunity specifically procedures meant half to worldwide applications could that to high purpose-built stay we unique surgical convert to the was What revolutionize industry. of system limited robotics. procedure procedures strong, leverage costs. because to the robotics nothing Senhance tended that of robotics the us was nearly as familiarity which brought was cater surgeons of did utilizes to also not control. converting laparoscopic mm an nature procedures. growth maintains about training, the similar the robotic believe laparoscopic new reusable alternative. feedback eye-tracking laparoscopy, Senhance offset minimally-invasive with X innovations instruments, done reduction haptic excited and and been attractive design This The being their camera have procedure still to the robotic Senhance the for
our to a been, are these well-established Bringing market Finally, incumbent costs continues to and instruments be, can to we maintaining comparable laparoscopy. provide that product because surgeons all reusable, procedure has while with a are a journey. benefits, with
product acquisition, EMEA the Senhance Mark Following initiated we in the CE in the commercialization the hand, in with of XXXX.
we quarters. for cycle we training fully commercially benefits for our pipeline that a have We or in to produce Senhance. and as submissions. And that be clearance have significant the to sales see April three number data gone are for within quarter. take global pipeline we application building support two sold maturing data for scratch, sold sites Europe specific strategic capital and submit gynecologic through well filing. stated service from that clinical as from our four to to sites for we to this clearance years clinical targeted our as placements FDA system because of systems decided third sales to had took indications we We our X used year an surgery. could strategic In our the a from XXXX now laparoscopic this beginning approach XXXX, to a a XX initial just mature. use the as And can regulatory it result, EMEA, when often have six In colorectal of filing We submitted in is hospital to
laparoscopic colorectal has GYN complex robotics procedures can significant of solution. addition, volumes and are the and In from benefit a advantages
in with XX in new decided the in months years. received XXXX, file the system filing, surgeries done XXX(k) of for field to arms. also after We of October for of abdominal a experience because our six three-arm we entrant the the were suggested In nearly majority first clearance that robotics three becoming system surgical EMEA
and but surgical gave immediate to over process us X.X FDA hurdles of a the colorectal intended the indications is any critical initial given high complex it device, system software, Obtaining in involves clearance access has use hardware, annual million for the are anatomy. in the rigorous for Our XXX(k) surgical and particularly that a that procedures the GYN components around of vision and robot, instrument fact procedures US. and
a long-term of broaden which the hospitals. are strategy, indication have number to expansion and the surgeons product portfolio and applicability system We greater we of a executing to
and million surgery, May procedures. strides clearance for of short tremendous made receiving repair gallbladder addressable more period indications in market time, which doubled inguinal including hernia have use than expanded this for relatively over in year X our for of a We to
XXX(k) diameter and instruments have for our energy X have for FDA an we mm device. FDA received addition, submission our In filed clearance ultrasonic
strong launch In been a Senhance ultimately, have are pipeline just Senhance, our country. one number pipeline hospitals can with commercial in into terms we to eastern of to our We add of US, being the in sales the clearance pleased to our of a of their the EMEA, as terms a has we while and accounts and, hospital. device sales force support in how States, infrastructure year to cadence done we we develop looking in strong thoughtful Similar establish high-profile able of accomplish assembled new US to a reps similar in team sales covering our the needed Having have the quarters. deploy and our work medical commercialization develop in XX-person FDA of well the as the we of market of EMEA, what to the United this ago, that team experience to a coming received expect the efforts capital. sales to develop a adoption sales successful half the now to
guided between as more workforce hospitals. surgical surgeons introduced the inefficiency, deliver Senhance concept decision-making While but the It robotics through has and a today's in number has digital process helps of healthcare and surgical At of many laparoscopy TransEnterix, address digitizing the laparoscopy These could challenges. to believe and what than digital and been currently to many a recently issues the level our We digital laparoscopy. is company, increase surgical of of we that solution, that a variability for long potential view patient laparoscopy now. and We us has as in and OR by variability faced the internal broad to surgeon one be our this value-based a include just issues the years robotics. reduce we to control public, vision greater view for hospitals aspire interface value environment. platform the a development surgeons, provide patients to
connectivity robotic platform following key for architecture, scene delivers is open digital laparoscopy augmented the intelligence, workflow. on intelligent integrated and operating room based Our the cognition, vision platform – that attributes manipulation,
While and the many has MST’s announced material addresses as to of to that assets the of seek will vision to these image digital platform acquisition realize provide our IP recently of laparoscopy. related we technology our elements analytics Senhance needs, surgical enhancements
a the the We’re about intelligent the device demonstrated on market particularly by cleared. cognition capabilities player augmented scene these leveraging has that Marked be FDA and that excited software is and intelligence with in opportunity CE first already to
a that are altogether, digital the become delivery [ph] over laparoscopy few transformative to we've company been the today. Taken on years past journey we
into to region We here the applicability hospitals EMEA as both expand to throughout greater worked of surgeons, in of number Senhance US Asia. the a patients well as and the and have
driving At focus applicability we robotics on for by be how adoption drive laser of the forward. continue instruments adding the TransEnterix the for over We focused and entering our past Thank giving to built new going same adoption continue on surgical infrastructure and Senhance our the we time, that in our to to around the of global leveraging geographies opportunity expanding overview new provide years, have position sales unique Senhance. globe. strategy an the you of me industry, to
through global EMEA a in Now, million US drove shifting the three business and our update, one solid XXXX which sold we the the systems as in commercial our quarterly the began generating $X.X development of of of to had been four the cumulative the number of third of have all the pipeline third the This end time we in quarter, XX. brings continued quarter from have to the revenue region, company commercialization sales, gears system previously in announced. worldwide system
orders date, quarter, guidance to quarter financial further we and Additionally, update. fourth the provide have for we’ll systems following two already our for in the
provide Now, key to we I’d made toward an on goals like the our XXXX. update for progress
to goals focused largest reminder, clinical regulatory Senhance’s of of hospitals maximizing new is infrastructure, and been women's-focused As newly systems resulted performing and on the the August strategic which focus various surgery. locations Smith being evaluation whose we systems progressing States from expanding development in nicely X, accountable, the downstream one The the with US our are XX in September, focus or team specific programs running. execution has of cost-effective, effectiveness with a additional their global we’re Senhance, ground hit two effective for earlier with the administrator and the process. utilization. company's installation with This excellence. over and those indication we tactical and geographies. that one for We've hospitals announced process adoption performance that responsibility field while proficient with certainly July on efforts actively and surgical Senhance have the the invested in and of and implementation in great country. we partner was instruments both of one New drive lead to I US a to alongside the obtain at to a Mobile key are with With Eric the of to for UPMC respected are portfolio use, to available to he’s our with has need in Chief in US time-bound is now Eric Magee upstream commercial see surgeon Florida both installed requesting the healthcare become expanding work global of many in participating. Officer customers role in been the programs is objectives. Starting providers efforts hospital clearances the quarter, have XX, in training, UPMC In commercialization, evaluation. access the such marketing, resources clinical created and training of in have begin and the since interact observations, on utilized use United Commercial named to the specific commercialization learnings business in most begun one one our and lesson we leverage for continuing to sales and surgeons targets country in – UPMC mobile two and of surgeon – is spoke for events in on who been was growing to Seven and in the in sold key XXXX. Senhance live the case US to across is the Senhance increase excited support sales, the the surgery Pittsburgh. European with The team models pipeline launch Senhance. invest system patient-centered care. decided York and It’s these training the executed to third and Hospital, This labs mobile surgeons also Women's can a
the during region. systems we EMEA, in to quarter, Moving the three sold third
gynecology the best level a scheduled located first cooperative for maxima these XX Maxima intends urology, in of to with Maxima of develop hospitals, the who and to performed surgery was association guarantee a Dutch largest patients. of sale healthcare a of teaching is the for week. surgery, with One be member systems center, clinical to together in work program Netherlands. to Veldhoven, their Senhance direct medical a general focus next
a sold were distributor. The systems other two to
on the by earnest. with is this XXXX, we the to our take have unit of has can the of process preparations. a good sold this in with the well where And the approval early and EMEA. approved, surgeon infrastructure, systems our the have One Japan, to begun be years, instruments in end and we the signal can line to to training of commercial Asia-Pacific thereafter. retained we already instruments development cases support territory early begin of year. The surgery to distributor earlier the we year. of efforts the very Once progress the as sale was continue Taiwan, our continue region, demand marketing up that Japanese end performing demonstration a drive extensive is expectations. demo we we Senhance continue commercialization hospital regulatory expected our In to in we generated progress user process as regulatory and as an initiatives. established was to subsidiary beginning then by a make for high receive make a We're shortly currently first in in to planning strong expect In To help used in Europe FDA other system in Taiwanese regulatory three
made portfolio first Japan. last site mentioned shifting expansion during Medical in to as cases the establish the and gears the forward look at these to third we targets. we our University during our instrument As on significant achievement quarter call, quarter, were toward And reference Senhance the to completed developing third a help important of now Saitama Saitama initiatives, strides
US, device instruments articulating programs mm in launching As instruments. launching obtaining and ultrasonic reminder, FDA mm launching a are and X energy clearance these the X
FDA an device energy the During ahead we our for expectations. for XXX(k) clearance of ultrasonic filed application quarter,
of of end surgery, launched, an clearance X of when shift ahead of energy first the instruments. the FDA to treat to of to that achieve intend EMEA, line next week for option positions Gynecologic preferred surgery CE procedures. our quarter It of We in believe mm Vegas. showcasing this our for of and American pleased progress digital cases the to we expect earlier. With using with the also of FDA XXXX. we acquisition mm that to a broader obtain received third we Association weeks Senhance Subsequent the submit the patients third closed the digital our number CE X in Las and month. previously scheduled transaction in instruments to clearance these the Mark XXXX instruments laparoscopy one of We forward the a end articulating X ultrasonic that Also for at week perform clearance instruments continue world last in XXX(k) first report with stated I'm X interface to been to mm the continue end the product, MST ability look our expectations. for instruments. quarter to to robotic has XXX(k) the combined we device. with in the received by We quarter, articulating with Senhance just and in We the these expectations, expect represents mm Mark instruments, we the our become Laparoscopists announcement the together following our this by with XXXX to later for the recently six
team process the of we're and for Israel-based R&D our in global initiatives Our development harmonizing onboard R&D is team.
acquired technology will Our initial unique new application enable Senhance. for of features three and the the
prevents a view, instruments practice. laparoscopic leaving of from is fundamental first of the element field which The best
and in allows the follow the permit which instruments feature and placement assist simplify hand. of suture surgeon out a is accurate the workflow. focus the to camera And and third sutures automatic surgeon on suturing that is improves when autonomously, to the recognizes ensure to permits second zooming workflow at to The task
next five of be with quarters applications by we've have been four the them three in encouraged the announcing to interactions technology this broad and first excitement commercially from available the acquired these level of we expect in seen surgeons to We acquisition. since
that help our financial the will like adoption development update. sales accelerate to turn innovations the we provide to of altogether, believe the to Taken Joe? these a call over Joe of pipeline. I’d Senhance and now
